Redeye gives its comment on IDL’s Q2 report. As estimated in our previous research note, the quarter saw a significant sales drop owing to down-priorities in the healthcare systems with the corona crisis. IDL guides for a better third quarter and we find it reasonable that FY 2020 sales could reach our forecasted SEK ~30 million, which would represent only a slight decrease in sales compared to last year’s figures. In this note, we share our impressions of the report, as well as our view on CEO Charlotte Berg’s resignation.